Introduction
============

Non-adherence to medication is an ever continuing complex and multidimensional health care problem. Adherence is defined as the process by which patients take their medication as agreed upon with their health care provider, composed of initiation, implementation and discontinuation ([@B55]). At these three phases non-adherent behavior could occur. Patients may not take the first dose of a prescribed medicine, deviate from the prescribed dosing regimen for example by taking less or skipping pills or discontinue treatment prematurely. Research shows that adherence to antihypertensive medication is suboptimal ([@B23]; [@B36]; [@B1]). This results in poorly controlled hypertension, higher risk of cardiovascular events, and increased health care costs ([@B10]; [@B6]; [@B19]). In Netherlands, community pharmacists are in the ideal position to address adherence, since they are medicines experts in primary care and the majority of patients receive their medication from a community pharmacy. In the past decades, numerous interventions in community pharmacies have been developed in order to increase medication adherence and improve treatment results ([@B2]; [@B5]). Unfortunately, in most studies the results on the effectiveness of these (pharmacist-led) interventions were disappointing ([@B32]; [@B22]; [@B53]; [@B30]; [@B54]; [@B39]). In only half of the studies the medication adherence was increased and in only a few studies the intervention led to improved treatment outcomes. One likely explanation is that most studies did not use a theoretical framework, crucial for understanding the complexities of adherence behavior. On top of that, most described interventions did not made an effort to apply a patient-tailored approach for identifying the specific causes or barriers for individual patients. Thus, in spite of substantial efforts, up till now little progress has been made to effectively tackle the persistent problem of medication non-adherence.

Because non-adherence is caused by multiple factors, categorized by the World Health Organization (WHO) as social/economic, patient-, condition-, therapy-, health care team, and system-related factors ([@B44]), interventions should be patient-tailored and designed according to a theoretical framework. A proven effective framework for behavioral change is the Common Sense Model of Self-regulation ([@B28], [@B27], [@B26]; [@B9]). According to this theory it is thought that patients seek to understand their illness by developing a representation of illness and treatment, which guides their health behavior. For example, if a patient regards hypertension as a problem, the patient will adopt health-related behavior (such as taking antihypertensive medication) in order to cope with the problem. Thus, adherence behavior will be influenced by whether it makes sense given patients' illness and treatment representations ([@B33]; [@B27]; [@B14], [@B16]; [@B42]; [@B41]). Moreover, given the asymptomatic nature of hypertension and the need for long-term medicine use, patients' understanding of the illness may be important in achieving long-term medication adherence ([@B33]).

Cardiovascular medication non-Adherence Tailored Intervention is a patient-tailored and pharmacist-led intervention program aimed to enhance self-reported adherence to antihypertensive medication, based on the Common Sense Model of Self-regulation ([@B52]). The CATI intervention program includes informing participants about hypertension and its consequences in order to change illness and treatment representations, identifying participants' barriers to adhere to medication and providing recommendations and deciding on interventions to overcome the identified barriers. In this paper, we report on the effectiveness of the CATI intervention program to enhance self-reported medication adherence compared to usual care.

Materials and Methods {#s1}
=====================

Study Design and Setting
------------------------

We performed a pragmatic parallel-group randomized controlled trial in 20 community pharmacies in rural and urban regions in Netherlands. Since this trial was pragmatic including more pharmacies was not possible. We included patients between March and June 2016 and followed them for nine months. Patients were randomly assigned to the intervention group executed by the pharmacist or control group executed by the pharmacy technician (allocation ratio 1:1). Blinding to treatment allocation was not possible due to the nature of the intervention. The study protocol has been described in more detail elsewhere ([@B52]). The Medical Ethics Committee of the VU University Medical Center approved the study, and all participants gave written informed consent. The study was performed in accordance with the Declaration of Helsinki (2008) and the Dutch Medical Research involving Human Subjects Act (WMO). The trial was registered in the Dutch Trial Register (NTR5017). For this paper, the EMERGE were followed ([@B8]).

Study Population
----------------

Patients aged 45--75 years using antihypertensive medication (including beta-blockers, calcium antagonists, diuretics, angiotensin converting enzyme (ACE) inhibitors, and angiotensin II-receptor antagonists) for at least twelve months and indicating to have hypertension by self-report were eligible to participate. We excluded patients who had insufficient Dutch language skills or used medication-intake supporting services provided by the pharmacy, i.e., repeat dispensing and pill packaging.

Patients non-adherent according to pharmacy dispensing data were selected using the selection method of the SFK, which is developed by the Royal Dutch Pharmacists Association ([@B46]). SFK registers information on dispensed drugs and calculates the Proportion of Days Covered (PDC). Patients with a PDC \< 80% for one antihypertensive drug class during the last six months were considered non-adherent ([@B37]). In each pharmacy a random sample of 75 patients was selected for inclusion using a randomization table. The selected patients were invited to participate and received the baseline questionnaire including the Medication Adherence Report Scale (MARS-5) ([@B12]). The MARS-5 assessed patients self-reported non-adherence to antihypertensive medication. Patients willing to participate were included if they were non-adherent based on both pharmacy dispensing data (PDC \< 80%) and the self-report questionnaire (MARS-5 \< 25). This study focused on medication adherence in the implementation phase of treatment ([@B55]).

Intervention Group
------------------

Participants in the intervention group received the CATI intervention program in addition to usual care. The program was executed by the pharmacist and included two consultations in the pharmacy. Participating pharmacists received a training on how to deliver the intervention program.

### First Consultation

The first consultation started with a semi-structured interview, called the QBS ([@B52]). The aim of the QBS was to explore participants' barriers to adhere to medication assessed with twelve questions. Based upon the identified barrier(s) at least one corresponding intervention module was selected according to the TIG ([@B52]). The TIG contains an overview of intervention recommendations divided in five intervention modules: (1) Providing Information, (2) Providing Tools, (3) Dealing with Side Effects, (4) Overcoming Practical Problems, and (5) Diminishing Negative Beliefs. The first consultation continued with discussing participants' illness and treatment representations and providing tailored information regarding potential risks of hypertension, use of medication and living a healthy lifestyle. Herewith, participants' understanding of hypertension and the perceived need to be adherent to antihypertensive treatment would be increased, which is emphasized as important for achieving long-term medication adherence by the Common Sense Model of Self-regulation ([@B33]). Subsequently, the pharmacist provided the participant with tailored recommendations from the selected intervention module to overcome the identified barriers. Finally, the participant received a written summary of the consultation including the information and recommendations provided.

### Follow-Up Consultation

Approximately three months after the first consultation, a follow-up consultation was planned with the participant. The purpose of this follow-up consultation was to discuss participants' implementation of and experiences with the discussed information and recommendations.

Control Group
-------------

Participants in the control group only received usual care according to the Dutch guidelines of the Royal Dutch Pharmacists Association ([@B20]). This care, usually delivered by a pharmacy technician, consist of checking and dispensing of prescribed drugs, providing instructions on medication use, and providing information about intended effects and possible side effects, during first and second dispensing. Blood pressure measurements in the control group were executed by the pharmacy technician.

Outcome Measures
----------------

Both intervention and control group participants received a questionnaire by post at baseline and after three, six and nine months. This comprehensive questionnaire assessed medication adherence, beliefs about medicines, quality of life and illness perceptions.

The primary outcome was self-reported medication adherence assessed with MARS-5 ([@B12]). The MARS-5 comprises five statements of adherence-related behavior: "I alter the dose of my medicines," "I stop taking my medicines for a while," "I decide to miss out on a dose of my medicines," "I forget to take my medicines," and "I take less of my medicines than instructed." Each statement is rated on a five-point scale, from 1 (always) to 5 (never). The MARS-5 sum score was calculated, ranging from 5 to 25 points where a higher score indicates better adherence. The MARS-5 sum score was also dichotomized, where a score below 25 points indicates non-adherence. The MARS-5 questionnaire is an easy-to-use tool and shows acceptable reliability and validity ([@B13]; [@B7]; [@B34]; [@B3]; [@B45]; [@B12]; [@B29]).

Secondary outcomes included participants' beliefs about medicines assessed with the validated and reliable Specific Beliefs about Medicines Questionnaire (BMQ) ([@B15]; [@B17]). The BMQ consists of ten questions scored on a 5-point Likert scale and is subdivided into a Necessity scale and Concern scale, both ranging from 5 to 25 points.

Participants' quality of life was assessed with the validated and reliable 12-Item Short Form (SF-12) questionnaire ([@B18]). The SF-12 questionnaire consists of twelve questions covering eight domains of health. The eight domains produces two summary scores including physical health (PCS) and mental health (MCS) both ranging from 0 to 100.

Participants' illness perceptions were assessed using the reliable and validated Brief Illness Perceptions Questionnaire (Brief IPQ-9) ([@B4]). The IPQ-9 is a nine-item scale designed to assess participants' cognitive and emotional representations of illness. All items except the causal question are rated on a 0 to 10 point scale.

Participants' systolic and diastolic blood pressure was measured three times during the nine months follow-up according to a standardized protocol. In the intervention group the pharmacist performed the measurements at the first consultation, at the follow-up consultation and at a final pharmacy visit. For the control group the blood pressure was measured by a pharmacy technician during three additionally scheduled pharmacy visits. At each visit the blood pressure was measured three times, each two minutes apart, in seated position with an automatic sphygmomanometer ([@B25]). Measured blood pressure was calculated as the mean of the second and third measurement values.

Sample Size
-----------

A sample size calculation for proportions, as described in the study protocol ([@B52]), was performed on a clinical relevant difference of 20% in percentage of adherent participants on the self-reported MARS-5. Based on this calculation a total sample size of 156 participants was required.

Statistical Analyses
--------------------

Descriptive statistics were used to describe patient characteristics. Means and standard deviations for continuous variables and frequencies and percentages for categorical variables were presented. For non-normal continuous outcomes medians with interquartile ranges were also provided. To compare baseline values between the intervention and control group independent sample *t*-tests and chi-square tests were used. The effect analyses of the intervention program by comparing the differences between the intervention and control group were performed according to the "intention-to-treat" principle. Linear mixed-model analyses were used for continuous outcomes, and logistic generalized estimating equation (GEE) analyses were used for dichotomous outcomes. Logistic GEE analyses were preferred over logistic mixed-model analyses because of the instability of the latter and the overestimation of the effect estimates ([@B50]). For all outcomes both an overall effect of the intervention program and effects of the intervention program at the different time points were estimated (three, six, and nine months). For each outcome variable crude regression coefficients were calculated (only adjusted for the baseline value of the particular outcome), as well as adjusted regression coefficients (adjusted for the baseline value of the particular outcome, the MARS-5 baseline score and possible confounders age, gender and education level). For the GEE analyses both crude and adjusted odds ratios (OR) were calculated. In addition to the main analyses, several sensitivity analyses were performed. First, a "per protocol" analyses was performed including all intervention participants that did visit the pharmacy for both the first and follow-up consultation. Second, several subgroup analyses were performed to stratify for gender, younger (45--55) and older (56--75) age and normal and high blood pressure measured at the first visit (baseline). Another subgroup analysis was performed including the intervention participants with ≥ 3 barriers identified with the QBS during the first consultation. A final subgroup analysis was performed using a more rigorous cut-off value for the primary outcome, including participants with a MARS-5 score of ≤ 23 at baseline ([@B31]; [@B47]). A score of \> 23 was considered adherent. Mixed-model and GEE analyses were performed using Stata/SE version 14.0 (StataCorp LP, College Station, TX, United States). All other analyses were performed using SPSS version 22.0 (IBM Corp, Armonk, NY, United States).

Results
=======

Baseline Characteristics
------------------------

**Figure [1](#F1){ref-type="fig"}** provides an overview of the flow of participants through the study. In total, 170 participants were included (85 in the intervention group and 85 in the control group). At baseline, the MARS-5 score was 0.9 points lower in the intervention group as compared to the control group, which indicates that the intervention group was significantly less adherent than the control group (mean difference -0.9 \[95% CI: -1.76 to -0.12\], *p* = 0.024) (**Table [1](#T1){ref-type="table"}**). No other relevant differences with respect to participant characteristics between the intervention and control group were found (**Table [1](#T1){ref-type="table"}**).

![Flow chart of the CATI study participants. AH, antihypertensive; MARS-5, Medication Adherence Report Scale; SFK, Foundation for Pharmaceutical Statistics.](fphar-09-01057-g001){#F1}

###### 

Baseline characteristics of participants of the CATI study.

  -------------------------------------------------------------------------------------------------------------------------------------------
                                                         Total study population\   Intervention group\   Control group\        *p*-value^c^
                                                         (*n* = 170)               (*n* = 85)            (*n* = 85)            
  ------------------------------------------------------ ------------------------- --------------------- --------------------- --------------
  Female gender                                          86 (50.6)                 44 (51.8)             42 (49.4)             0.759

  Age                                                    61.1 ± 7.9                60.3 ± 7.9            61.9 ± 7.9            0.208

  **Origin**\                                            \                         \                     \                     0.457
  Dutch native\                                          151 (88.8)\               78 (91.8)\            73 (85.9)\            
  Immigrant, Western\                                    9 (5.3)\                  3 (3.5)\              6 (7.1)\              
  Immigrant, non-Western                                 10 (5.9)                  4 (4.7)               6 (7.1)               

  **Education level**\                                   \                         \                     \                     0.791
  Low\                                                   43 (25.3)\                23 (27.1)\            20 (23.5)\            
  Moderate\                                              66 (38.8)\                31 (36.5)\            35 (41.2)\            
  High                                                   61 (35.9)                 31 (36.5)             30 (35.3)             

  **Employment status**\                                 \                         \                     \                     \
  Working                                                72 (42.4)                 38 (44.7)             34 (40.0)             0.535

  **Living situation**\                                  \                         \                     \                     \
  Alone                                                  28 (16.5)                 10 (11.8)             18 (21.2)             0.098

  **Alcohol use**\                                       \                         \                     \                     \
  Yes                                                    118 (69.4)                59 (69.4)             59 (69.4)             1.000

  **Tobacco use**\                                       \                         \                     \                     \
  Yes                                                    15 (8.8)                  6 (7.1)               9 (10.6)              0.417

  No. of cardiovascular diseases                         1.9 ± 1.0                 1.9 ± 1.1             1.9 ± 0.9             0.765

  No. of total prescribed medicines                      4.1 ± 2.6                 4.0 ± 2.7             4.1 ± 2.4             0.811

  No. of antihypertensive medicines                      1.8 ± 0.8                 1.8 ± 0.8             1.8 ± 0.8             0.927

  **Antihypertensive medicines**\                        \                         \                     \                     \
  Beta blockers\                                         59 (34.7)\                30 (35.3)\            29 (34.1)\            0.872\
  Calcium antagonists\                                   54 (31.8)\                28 (32.9)\            26 (30.6)\            0.742\
  Diuretics\                                             56 (32.9)\                27 (31.8)\            29 (34.1)\            0.744\
  ACE inhibitors / angiotensin II-receptor antagonists   124 (72.9)\               60 (70.6)             64 (75.3)             0.490

  **Blood pressure (mmHg)^a^**\                          \                         \                     \                     \
  Systolic\                                              143.2 ± 17.6\             145.3 ± 16.0\         140.8 ± 19.0\         0.131\
  Diastolic                                              86.7 ± 12.7               88.0 ± 12.5           85.2 ± 12.9           0.191

  **High blood pressure^a,b^**\                          \                         \                     \                     \
  Yes                                                    80 (57.1)                 46 (63.0)             34 (50.7)             0.143

  **Medication adherence (MARS-5)**                                                                                            

  Sum score (5--25)                                      22.1 ± 2.7\               21.6 ± 3.1\           22.5 ± 2.2\           0.024^∗^
                                                         23 (21 to 24)             23 (21.0 to 24.0)     23.0 (22.0 to 24.0)   

  **Quality of life (SF-12)**\                           \                         \                     \                     \
  PCS (0--100)\                                          46.3 ± 10.1\              45.7 ± 10.2\          46.9 ± 10.0\          0.438
                                                         49.9 (39.2 to 54.2)       49.3 (38.7 to 53.9)   50.8 (42.2 to 54.2)   

  MCS (0--100)                                           52.7 ± 8.3\               53.1 ± 7.7\           52.3 ± 8.9\           0.508
                                                         55.4 (49.7 to 57.9)       55.2 (48.9 to 58.6)   55.7 (50.7 to 57.7)   

  **Beliefs about medicines (BMQ)**                                                                                            

  Necessity (5--25)                                      15.6 ± 4.2                15.6 ± 4.4            15.7 ± 4.1            0.813

  Concern (5--25)                                        12.6 ± 3.7                12.9 ± 3.7            12.3 ± 3.7            0.277

  **Illness Perceptions (IPQ-9)**\                       \                         \                     \                     \
  Consequences (0--10)\                                  3.3 ± 2.8\                3.7 ± 2.8\            2.9 ± 2.7\            0.083
                                                         3.0 (1.0 to 6.0)          3.0 (1.0 to 6.0)      2.0 (0.0 to 5.0)      

  Timeline (0--10)                                       8.2 ± 2.5\                8.4 ± 2.3\            8.1 ± 2.7\            0.417
                                                         9.0 (7.0 to 10.0)         10.0 (7.0 to 10.0)    9.0 (7.0 to 10.0)     

  Personal control (0--10)                               5.2 ± 2.4                 5.0 ± 2.5             5.3 ± 2.3             0.423

  Treatment control (0--10)                              7.4 ± 1.9\                7.4 ± 1.8\            7.4 ± 1.9\            0.986
                                                         8.0 (7.0 to 9.0)          8.0 (7.0 to 9.0)      7.0 (6.5 to 9.0)      

  Identity (0--10)                                       3.2 ± 2.8\                3.5 ± 2.8\            2.9 ± 2.7\            0.133
                                                         3.0 (0.0 to 5.25)         3.0 (1.0 to 6.0)      2.0 (0.0 to 5.0)      

  Illness concerns (0--10)                               4.7 ± 2.8                 4.7 ± 2.9             4.7 ± 2.8             0.978

  Coherence (0--10)                                      6.0 ± 2.7                 5.9 ± 3.0             6.1 ± 2.4             0.548

  Emotional representation (0--10)                       2.7 ± 2.7\                2.7 ± 2.5\            2.6 ± 2.9\            0.842
                                                         2.0 (0.0 to 5.0)          2.0 (0.0 to 5.0)      2.0 (0.0 to 4.0)      

                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: BMQ, Specific Beliefs about Medicines Questionnaire; IPQ-9, Illness Perceptions Questionnaire; MARS-5, Medication Adherence Report Scale; MCS, Mental Component Score; PCS, Physical Component Score; SD, standard deviation; SF-12, 12-item Short Form.

a

Data from 30 participants is missing.

b

High blood pressure is defined as an elevated blood pressure exceeding 140 mm Hg in systolic phase and or 90 mm Hg in diastolic phase.

c

Independent sample

t

-tests and chi-square tests were used to test for differences between the intervention and control group.

∗

Statistically significant.

Declined to Participate and Non-responders
------------------------------------------

In total, 1338 patients were invited to participate. Of them, 108 (8.1%) did not meet the inclusion criteria, 208 (15.5%) declined to participate, and 852 (63.7%) did not respond (**Figure [1](#F1){ref-type="fig"}**). Patients who declined to participate did not differ in gender from participants, however, they were significantly older (*p* ≤ 0.001) and had a lower level of education (*p* = 0.005). Reasons indicated for non-participation were no interest, no time, or not needed according to the patient. Gender and age of non-responders were comparable to participants.

Intervention Program
--------------------

The first consultation of the intervention program was held with 75 participants (88.2%) and the follow-up consultation with 66 participants (77.6%). The average period between the first and follow-up consultation was 94 days. In most cases missed consultations were due to logistic and time management problems of pharmacists. The average time of the first and follow-up consultation was 36 min (range: 15--85 min) and 20 min (range: 5--45 min), respectively. Participants who did not attend both consultations did not differ in age, gender, origin, education level, employment status or living situation from participants who did attend both consultations, however, they used significantly more antihypertensive medicines (*p* = 0.044).

Primary Outcome
---------------

**Table [2A](#T2a){ref-type="table"}** presents the mean scores and proportions of the primary outcome. In the "intention-to-treat" analysis, no significant differences were found in self-reported adherence over time or after three, six and nine months between the intervention and control group (**Table [3A](#T3a){ref-type="table"}**). Results of the sensitivity analyses are presented in **Appendix [A](#SM1){ref-type="supplementary-material"}**. Per protocol and most subgroup analyses did not show different results. However, in the subgroup analysis in which we only included participants with ≥ 3 barriers identified during the first consultation, a significant intervention effect was found on self-reported medication adherence after nine months (mean difference 0.84 \[95% CI: 0.03 to 1.65\], *p* = 0.042). In the subgroup analysis where we used a more rigorous cut-off value for the MARS-5 score, a more positive intervention effect was found (mean difference 0.43 \[95% CI: -0.30 to 1.15\]), however, not statistically significant.

###### 

Mean scores ± SD and proportions (%) of the primary and secondary outcomes at each measurement point.

                                                          Baseline        T1        T2              T3                                                  
  ---------------------------------------- -------------- --------------- --------- --------------- --------- --------------- --------- --------------- ---------
  **Primary outcome**                                                                                                                                   
  MARS-5 sum score                         Intervention   21.6 ± 3.1      85        22.5 ± 2.5      82        22.7 ± 2.4      77        22.8 ± 2.3      66
                                           Control        22.5 ± 2.2      85        23.0 ± 1.9      77        22.9 ± 2.2      76        23.1 ± 2.3      70
                                                                                                                                                        
                                                          ***n (%)***     ***n***   ***n (%)***     ***n***   ***n (%)***     ***n***   ***n (%)***     ***n***
                                                                                                                                                        
  MARS-5 (\< 25)                           Intervention   85 (100)        85        71 (86.6)       82        65 (84.4)       77        57 (86.4)       66
                                           Control        85 (100)        85        64 (83.1)       77        65 (85.5)       76        55 (78.6)       70
                                                                                                                                                        
                                                          **Mean ± SD**   ***n***   **Mean ± SD**   ***n***   **Mean ± SD**   ***n***   **Mean ± SD**   ***n***
                                                                                                                                                        
  **Secondary outcomes**                                                                                                                                
  SF-12 PCS (0--100)                       Intervention     45.7 ± 10.2   85        45.5 ± 9.6      82          46.0 ± 10.3   77          46.0 ± 10.2   66
                                           Control          46.9 ± 10.0   85        46.6 ± 8.8      77        46.5 ± 9.0      74        46.3 ± 9.7      70
  SF-12 MCS (0--100)                       Intervention   53.1 ± 7.7      85        53.2 ± 7.5      82        52.9 ± 8.0      77        52.9 ± 8.3      66
                                           Control        52.3 ± 8.9      85        53.6 ± 8.0      77        53.0 ± 8.4      74        52.5 ± 8.7      70
  BMQ Necessity (5--25)                    Intervention   15.6 ± 4.4      85        15.8 ± 4.3      82        16.2 ± 4.5      77        16.9 ± 4.4      66
                                           Control        15.7 ± 4.1      85        15.7 ± 4.0      77        16.1 ± 4.5      76        16.0 ± 4.2      70
  BMC Concern (5--25)                      Intervention   12.9 ± 3.7      85        13.1 ± 3.9      82        12.5 ± 4.1      77        12.6 ± 3.9      66
                                           Control        12.3 ± 3.7      85        12.7 ± 3.9      77        12.3 ± 4.4      76        12.4 ± 3.9      70
  IPQ-9 Consequences (0--10)               Intervention     3.7 ± 2.8     85          3.3 ± 2.5     82          3.5 ± 2.7     77          3.7 ± 2.8     66
                                           Control          2.9 ± 2.7     85          3.3 ± 2.6     77          3.5 ± 2.7     76          3.4 ± 2.8     70
  IPQ-9 Timeline (0--10)                   Intervention     8.4 ± 2.3     84          8.5 ± 2.0     81          8.4 ± 2.3     77          8.5 ± 2.4     66
                                           Control          8.1 ± 2.7     85          8.1 ± 2.5     75          7.9 ± 2.6     76          8.2 ± 2.4     69
  IPQ-9 Personal control (0--10)           Intervention     5.0 ± 2.5     85          5.6 ± 2.3     81          5.4 ± 2.4     77          5.6 ± 2.3     66
                                           Control          5.3 ± 2.3     85          5.8 ± 2.3     76          5.8 ± 2.4     76          5.9 ± 2.3     69
  IPQ-9 Treatment control (0--10)          Intervention     7.4 ± 1.8     84          7.5 ± 2.0     81          7.4 ± 2.2     77          7.6 ± 1.8     66
                                           Control          7.4 ± 1.9     85          7.6 ± 1.7     75          7.4 ± 1.9     76          7.8 ± 1.6     69
  IPQ-9 Identity (0--10)                   Intervention     3.5 ± 2.8     85          3.2 ± 2.7     82          3.2 ± 2.7     77          3.2 ± 2.6     66
                                           Control          2.9 ± 2.7     85          2.9 ± 2.7     77          3.1 ± 2.7     76          3.2 ± 2.9     70
  IPQ-9 Illness concerns (0--10)           Intervention     4.7 ± 2.9     85          4.8 ± 2.9     81          4.7 ± 2.7     77          4.8 ± 2.9     66
                                           Control          4.7 ± 2.8     85          4.5 ± 2.6     76          4.2 ± 2.9     76          4.3 ± 2.7     70
  IPQ-9 Coherence (0--10)                  Intervention     5.9 ± 3.0     85          6.2 ± 2.6     82          6.3 ± 2.8     77          6.3 ± 2.7     66
                                           Control          6.1 ± 2.4     85          6.2 ± 2.7     76          5.8 ± 2.7     76          6.4 ± 2.4     69
  IPQ-9 Emotional representation (0--10)   Intervention     2.7 ± 2.5     85          2.6 ± 2.4     81          2.7 ± 2.7     77          3.3 ± 2.9     66
                                           Control          2.6 ± 2.9     85          2.6 ± 2.5     76          2.9 ± 2.9     76          2.9 ± 2.8     70
                                                                                                                                                        

BMQ, Specific Beliefs about Medicines Questionnaire; IPQ-9, Illness Perceptions Questionnaire; MARS-5, Medication Adherence Report Scale; MCS, Mental Component Score; PCS, Physical Component Score; SD, standard deviation, SF-12, 12-item Short Form.

###### 

Mean scores ± SD of systolic and diastolic blood pressure measurements at three visits during study period.

                                            Visit 1 (baseline)   Visit 2   Visit 3                              
  -------------------------- -------------- -------------------- --------- --------------- ---- --------------- ----
  **Secondary outcomes**                                                                                        
  Systolic blood pressure    Intervention   145.3 ± 16.0         73        142.9 ± 19.0    66   145.1 ± 16.7    55
                             Control        140.8 ± 19.0         67        140.0 ± 17.8    65   142.9 ± 17.4    55
  Diastolic blood pressure   Intervention     88.0 ± 12.5        73          88.1 ± 13.9   66     87.3 ± 13.6   55
                             Control          85.2 ± 12.9        67          85.6 ± 12.5   65     86.7 ± 12.2   55
                                                                                                                

SD, standard deviation.

###### 

Intervention effects from linear mixed model and logistic GEE analyses of the primary outcome and secondary outcomes.

                                   Overall effect            T1              T2                        T3                                                                                  
  -------------------------------- ------------------------- --------------- ------------------------- --------------- ------------------------- --------------- ------------------------- ---------------
  **Primary outcome**                                                                                                                                                                      
  MARS-5 sum score                                                                                                                                                                         
     Crude^a^                      0.17 (--0.29 to 0.62)     0.472           --0.05 (--0.59 to 0.48)   0.851           0.34 (--0.20 to 0.88)     0.220           0.27 (--0.30 to 0.83)     0.354
     Adjusted^b^                   0.18 (--0.27 to 0.63)     0.440           --0.04 (--0.57 to 0.49)   0.874           0.35 (--0.18 to 0.89)     0.198           0.27 (--0.28 to 0.83)     0.337
                                                                                                                                                                                           
                                   **OR (95% CI)**           ***p-value***   ***OR (95% CI)***         ***p-value***   ***OR (95% CI)***         ***p-value***   ***OR (95% CI)***         ***p-value***
                                                                                                                                                                                           
  MARS-5 (\<25)                                                                                                                                                                            
     Crude                         1.03 (0.94 to 1.13)       0.467           1.04 (0.93 to 1.16)       0.543           0.99 (0.88 to 1.10)       0.812           1.09 (0.96 to 1.24)       0.179
     Cdjusted                      1.03 (0.94 to 1.13)       0.505           1.03 (0.92 to 1.16)       0.577           0.98 (0.88 to 1.10)       0.765           1.09 (0.96 to 1.23)       0.190
                                                                                                                                                                                           
                                   **Difference (95% CI)**   ***p*-value**   **Difference (95% CI)**   ***p*-value**   **Difference (95% CI)**   ***p*-value**   **Difference (95% CI)**   ***p*-value**
                                                                                                                                                                                           
  **Secondary outcomes**                                                                                                                                                                   
  SF-12 PCS                                                                                                                                                                                
     Crude                         --0.41 (--2.08 to 1.26)   0.631           --0.61 (--2.64 to 1.43)   0.558           --0.28 (--2.35 to 1.80)   0.794           --0.33 (--2.48 to 1.82)   0.764
     Adjusted                      --0.10 (--1.77 to 1.58)   0.911           --0.29 (--2.33 to 1.75)   0.781           0.04 (--2.04 to 2.11)     0.971           --0.02 (--2.18 to 2.13)   0.984
  SF-12 MCS                                                                                                                                                                                
     Crude                         --0.55 (--2.33 to 1.22)   0.541           --0.94 (--3.04 to 1.15)   0.378           --0.54 (--2.67 to 1.60)   0.622           --0.15 (--2.35 to 2.10)   0.896
     Adjusted                      --0.84 (--2.63 to 0.96)   0.362           --1.22 (--3.34 to 0.89)   0.258           --0.81 (--2.96 to 1.34)   0.460           --0.45 (--2.67 to 1.78)   0.695
  BMQ Necessity                                                                                                                                                                            
     Crude                         0.68 (--0.03 to 1.38)     0.060           0.40 (--0.52 to 1.31)     0.393           0.54 (--0.38 to 1.47)     0.250           1.23 (0.25 to 2.20)       0.013^∗^
     Adjusted                      0.70 (--0.01 to 1.42)     0.054           0.43 (--0.50 to 1.35)     0.366           0.57 (--0.36 to 1.51)     0.230           1.25 (0.27 to 2.24)       0.012^∗^
  BMQ Concern                                                                                                                                                                              
     Crude                         --0.11 (--0.88 to 0.65)   0.773           0.03 (--0.87 to 0.94)     0.944           --0.11 (--1.02 to 0.81)   0.818           --0.35 (--1.30 to 0.60)   0.465
     Adjusted                      --0.12 (--0.90 to 0.65)   0.755           0.02 (--0.89 to 0.93)     0.963           --0.12 (--1.04 to 0.81)   0.804           --0.36 (--1.32 to 0.59)   0.455
  IPQ-9 Consequences                                                                                                                                                                       
     Crude                         --0.29 (--0.80 to 0.22)   0.271           --0.31 (--0.93 to 0.31)   0.331           --0.34 (--0.98 to 0.29)   0.288           --0.17 (--0.83 to 0.49)   0.612
     Adjusted                      --0.34 (--0.85 to 0.17)   0.187           --0.36 (--0.98 to 0.26)   0.257           --0.40 (--1.03 to 0.23)   0.217           --0.23 (--0.89 to 0.42)   0.488
  IPQ-9 Timeline                                                                                                                                                                           
     Crude                         0.28 (--0.22 to 0.77)     0.270           0.23 (--0.40 to 0.86)     0.470           0.31 (--0.32 to 0.94)     0.336           0.29 (--0.37 to 0.96)     0.386
     Adjusted                      0.27 (--0.24 to 0.77)     0.298           0.22 (--0.42 to 0.86)     0.497           0.30 (--0.34 to 0.94)     0.358           0.29 (--0.39 to 0.96)     0.404
  IPQ-9 Personal control                                                                                                                                                                   
     Crude                         --0.03 (--0.53 to 0.46)   0.893           0.00 (--0.65 to 0.65)     0.997           --0.15 (--0.80 to 0.51)   0.655           0.07 (--0.62 to 0.76)     0.835
     Adjusted                      --0.06 (--0.56 to 0.44)   0.815           --0.03 (--0.68 to 0.63)   0.937           --0.18 (--0.84 to 0.49)   0.602           0.05 (--0.65 to 0.75)     0.887
  IPQ-9 Treatment control                                                                                                                                                                  
     Crude                         0.08 (--0.33 to 0.49)     0.701           0.06 (--0.44 to 0.57)     0.800           0.20 (--0.31 to 0.71)     0.440           --0.04 (--0.57 to 0.49)   0.892
     Adjusted                      0.09 (--0.32 to 0.50)     0.669           0.08 (--0.43 to 0.58)     0.766           0.21 (--0.30 to 0.72)     0.421           --0.03 (--0.56 to 0.51)   0.923
  IPQ-9 Identity                                                                                                                                                                           
     Crude                         --0.20 (--0.70 to 0.30)   0.427           --0.12 (--0.71 to 0.48)   0.700           --0.18 (--0.78 to 0.42)   0.566           --0.33 (--0.95 to 0.30)   0.302
     Adjusted                      --0.26 (--0.75 to 0.23)   0.293           --0.18 (--0.77 to 0.41)   0.551           --0.23 (--0.83 to 0.36)   0.439           --0.39 (--1.01 to 0.23)   0.214
  IPQ-9 Illness concerns                                                                                                                                                                   
     Crude                         0.39 (--0.17 to 0.95)     0.174           0.23 (--0.43 to 0.90)     0.497           0.49 (--0.18 to 1.16)     0.154           0.45 (--0.24 to 1.15)     0.202
     Adjusted                      0.30 (--0.26 to 0.85)     0.296           0.14 (--0.52 to 0.80)     0.681           0.40 (--0.27 to 1.10)     0.245           0.36 (--0.34 to 1.05)     0.312
  IPQ-9 Coherence                                                                                                                                                                          
     Crude                         0.32 (--0.24 to 0.87)     0.265           0.16 (--0.55 to 0.87)     0.654           0.76 (0.04 to 1.48)       0.040^∗^        --0.01 (--0.77 to 0.75)   0.986
     Adjusted                      0.34 (--0.20 to 0.89)     0.220           0.19 (--0.51 to 0.90)     0.591           0.78 (0.06 to 1.49)       0.034^∗^        0.03 (--0.72 to 0.79)     0.929
  IPQ-9 Emotional representation                                                                                                                                                           
     Crude                         --0.09 (--0.58 to 0.40)   0.717           --0.17 (--0.77 to 0.44)   0.587           --0.26 (--0.87 to 0.35)   0.406           0.24 (--0.39 to 0.88)     0.454
     Adjusted                      --0.12 (--0.61 to 0.37)   0.620           --0.20 (--0.81 to 0.40)   0.511           --0.29 (--0.91 to 0.32)   0.347           0.22 (--0.42 to 0.86)     0.509
                                                                                                                                                                                           

BMQ, Specific Beliefs about Medicines Questionnaire; CI, confidence interval; GEE, Generalized Estimating Equation; IPQ-9, Illness Perceptions Questionnaire; MARS-5, Medication Adherence Report Scale; MCS, Mental Component Score; OR, Odds Ratio; PCS, Physical Component Score; SF-12, 12-item Short Form.

a

Corrected for baseline value of the particular outcome.

b

Additionally corrected for MARS-5 score at baseline and possible confounders age, gender and education level.

∗

Statistically significant.

###### 

Intervention effects from linear mixed model of the clinical secondary outcome.

                                 Overall effect          Visit 2   Visit 3                                                   
  ------------------------------ ----------------------- --------- ----------------------- ------- ------------------------- -------
  **Systolic blood pressure**                                                                                                
  Crude^a^                       1.32 (--2.83 to 5.47)   0.533     2.14 (--2.78 to 7.07)   0.394   0.30 (--5.03 to 5.62)     0.913
  Adjusted^b^                    1.52 (--2.71 to 5.75)   0.481     2.30 (--2.69 to 7.29)   0.366   0.56 (--4.83 to 5.96)     0.838
  **Diastolic blood pressure**                                                                                               
  Crude                          0.93 (--2.30 to 4.15)   0.573     1.79 (--1.90 to 5.48)   0.342   --0.17 (--4.13 to 3.79)   0.932
  Adjusted                       0.63 (--2.65 to 3.92)   0.706     1.49 (--2.25 to 5.23)   0.435   --0.46 (--4.47 to 3.55)   0.822
                                                                                                                             

CI, confidence interval.

a

Corrected for baseline value of the particular outcome.

b

Additionally corrected for MARS-5 score at baseline and possible confounders age, gender and education level.

Secondary Outcomes
------------------

In **Tables [2A](#T2a){ref-type="table"}**,**[B](#T2b){ref-type="table"}** the mean scores of the secondary outcomes are listed. For the quality of life (SF-12), the illness perceptions (IPQ-9) and the systolic and diastolic blood pressure, no significant differences over time or at the different time points between the intervention and control group were found (**Tables [3A](#T3a){ref-type="table"}**,**[B](#T3b){ref-type="table"}**). For the beliefs about medicines, a borderline significant difference over time was found on the BMQ Necessity scale (**Tables [3A](#T3a){ref-type="table"}**,**[B](#T3b){ref-type="table"}**). This overall effect was found because participants in the intervention group had a significantly higher BMQ Necessity score at nine months follow-up (mean difference 1.25 \[95% CI: 0.27 to 2.24\], *p* = 0.012). This means that they had significantly stronger beliefs about the necessity of using their medicines as compared to the control group.

Discussion
==========

The aim of this study was to evaluate the effectiveness of the CATI intervention program to enhance self-reported adherence to antihypertensive medication as compared to usual care. There were no statistically significant effects in adherence-related behavior, quality of life, illness perceptions, beliefs about medicines (concern scale), and blood pressure. For the beliefs about medicines, we did find a statistical significant intervention effect on the BMQ Necessity scale after nine months.

A systematic review of [@B11] reported that only 35.1% of comparable intervention studies aimed to directly improve adherence in patients with hypertension did significantly improve medication adherence. In studies with quite comparable intervention programs inconsistent findings were reported ([@B35]; [@B48]; [@B38]). For example, in a study of [@B35] a pharmaceutical care program including two counseling visits to the pharmacy in patients using antihypertensive medication was evaluated. They reported statistically significant effects on both blood pressure control and self-reported medication adherence at nine months. In a study of [@B48] patients visited the pharmacy three times and received a package of interventions, including motivational interviewing, medication review and prescription refill reminders. They concluded that the intervention had a significant effect on blood pressure, but not on medication adherence. In a study of [@B38] a multifaceted medication management intervention for patients with hypertension, type 2 diabetes or other cardiovascular disease significantly improved medication adherence. This study also found that intervention patients had significantly stronger necessity beliefs compared to control patients. This latter result is in line with the finding of our study.

There are several possible explanations for the absence of effects on medication adherence-related behavior in our study. First, the design of our study was a parallel-group randomized controlled trial in which individuals within one pharmacy were randomized into the intervention or control group. It might have been better to apply cluster randomization to control for contamination across groups. However, to avoid contamination in our study the intervention group was executed by the pharmacist, whereas the control group was executed by the pharmacy technician. Second, since large numbers of patients did not respond (63.7%) and declined to participate (15.5%) we cannot rule out selection bias. It might be possible that we missed patients that were unaware of their incompetence to properly use their medicines and therefore did not score non-adherent on the self-reported questionnaire. In addition, patients with strong negative beliefs toward medicines are probably not responsive for participation in intervention studies, while these patients are the population most interesting to target. With respect to drop-out, participants who did not attend the consultations used significantly more antihypertensive medicines compared to participants who did attend both consultations. This can be seen as a limitation, since patients with multiple medicines will benefit most from counseling interventions. However, we consider the bias of study results limited because in most cases the reason for not performing a consultation were logistic and time management problems of pharmacists. Third, the absence of effects could be related to the eligibility criteria of the study population, especially with regard to the outcome measure. There has been some debate about the appropriateness of MARS-5 as a medication adherence measure in the literature ([@B51]; [@B49]). An explanation for these inconsistent results could be the use of pharmacy refill data as reference standard, since this measures another underlying construct compared to self-reported questionnaires. However, a large number of studies have shown acceptable validity and reliability of MARS-5 and therefore we have chosen this measure for this study ([@B7]; [@B34]; [@B3]; [@B45]; [@B12]; [@B29]). The chosen cut-off value for MARS-5 might be a plausible explanation for the absence of effects. A self-reported MARS-5 score of below 25 points, indicates marginally non-adherent behavior. This resulted in too little room for improvement. Results of the sensitivity analysis on participants with lower self-reported adherence at baseline (MARS-5 ≤ 23) were more positive than the main analysis. It may, therefore, be more efficient to target an intervention like this on patient groups with a lower degree of adherence. Another outcome measure limitation included that we were not able to collect pharmacy refill data after baseline. Because if a participant started repeat dispensing (medication-intake supporting service of pharmacy) during the study period, the dispensing was regulated and therefore participants could no longer be identified as non-adherent with the SFK selection method. Since pharmacy refill data could not be collected, we were not able to combine two different methods to assess medication adherence, a strategy that has been suggested in the literature ([@B44]; [@B24]). A patient group who experiences multiple barriers to adhere to medication and therefore might deal with more structural adherence problems, might also be more eligible for this kind of intervention. This is confirmed by the more positive and significant intervention effects in the sensitivity analyses on participants with ≥ 3 identified barriers. Since only 57% of participants had an uncontrolled blood pressure at baseline, using uncontrolled blood pressure as an eligibility criterion in adherence-enhancing interventions must be considered. However, it might also be important to target both patients with or without uncontrolled blood pressure, since non-adherent behavior is continuous and dynamic and can occur over time ([@B44]). Fourth, since we only found a significant effect in the main analyses on the BMQ Necessity scale after nine months, it might be possible that improvement of actual adherence-related behavior can only be expected after a longer period of time ([@B15]; [@B43]; [@B41]). In the literature the Stages of Change model describes that health-related behavior change is rarely easy and requires a gradual progression of small steps ([@B40]). In early stages, becoming more aware of the need for treatment, is an important factor for the beginning of small changes in behavior. It might, therefore, be more efficient to target patients in the initiation phase of medicine-taking (at the start of therapy). For instance, a study testing a pharmacist telephone counseling intervention found improvements in medication adherence in patients initiating therapy ([@B21]). In contrast, it might also be efficient to target patients with long-term medication use, since these patients might experience treatment fatigue and therefore are at risk for medication non-adherence. Finally, since no effects were found on participants' illness perceptions, the use of the Common Sense Model of Self-regulation as a foundation of adherence-enhancing interventions must be reconsidered.

Implications for Practice and Research
--------------------------------------

Based on the results, we do not recommend to implement the CATI intervention program in the current form for the population selected in this study. The chosen cut-off value of MARS-5 might have been too liberal resulting in including participants with only marginally non-adherent behavior. Future studies should focus on how to select eligible patient groups with appropriate measures in order to effectively target adherence-enhancing interventions. Study populations with more severe non-adherent behavior and more barriers to adhere to medication, might benefit more from interventions, which is also confirmed by the more positive results of our sensitivity analyses. Future studies should also explore whether uncontrolled blood pressure should be added as an eligibility criterion. Moreover, future research might focus more on raising awareness and patients' necessity beliefs of using medicines, in order to change patients' adherence-related behavior. Finally, a process evaluation study would provide more insight into whether the ineffectiveness of the CATI intervention program was due to poor implementation or inadequacies of the intervention itself.
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:   cardiovascular medication non-adherence tailored intervention

EMERGE

:   ESPACOMP medication adherence reporting guidelines
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